PSNL 7.34 ▲ 8.42% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Personalis Inc.

    NASDAQ: PSNL · Real-Time Price · USD
    7.34
    0.57 (8.42%)
    At close: Oct 03, 2025, 3:59 PM
    7.30
    -0.52%
    After-hours: Oct 03, 2025, 07:20 PM EDT
    8.42%
    Bid 7.2
    Market Cap 650.89M
    Revenue (ttm) 80.32M
    Net Income (ttm) -91.32M
    EPS (ttm) -1.25
    PE Ratio (ttm) -5.87
    Forward PE -7.36
    Analyst Buy
    Dividends n/a
    Ask 7.48
    Volume 1,276,826
    Avg. Volume (20D) 1,005,231
    Open 6.77
    Previous Close 6.77
    Day's Range 6.77 - 7.40
    52-Week Range 2.83 - 7.79
    Beta 1.83
    Ex-Dividend Date n/a

    About PSNL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PSNL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PSNL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Personalis Inc. is scheduled to release its earnings on Nov 5, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 weeks ago
    +13.17%
    Personalis shares are trading higher after the com... Unlock content with Pro Subscription
    1 month ago
    -21.81%
    Personalis shares are trading lower after the company reported a Q2 revenue miss, issued Q3 sales guidance below estimates, and cut its FY25 sales guidance.
    news image

    2 weeks ago · businesswire.com

    Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant...

    news image

    3 weeks ago · businesswire.com

    CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

    FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale C...

    news image

    1 month ago · businesswire.com

    Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

    FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (N...

    news image

    1 month ago · zacks.com

    Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)

    The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...

    news image

    1 month ago · zacks.com

    After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)

    Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...

    news image

    1 month ago · zacks.com

    All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy

    Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · benzinga.com

    Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

    U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.

    news image

    1 month ago · fool.com

    Personalis (PSNL) Q2 Revenue Falls 24%

    Personalis (PSNL) Q2 Revenue Falls 24%

    news image

    2 months ago · seekingalpha.com

    Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

    Personalis, Inc. (NASDAQ:PSNL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Aaron L. Tachibana - CFO & COO Christopher M.

    news image

    2 months ago · businesswire.com

    Personalis Reports Second Quarter 2025 Financial Results

    FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, an...

    Add to Watchlist